Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

FDA takes action against unapproved single-ingredient oral colchicine

The U.S. Food and Drug Administration took action against companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of Familial Mediterranean Fever (FMF).

1 Oct 2010

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010. The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission and is available on the Company's website.

30 Sep 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

Catalent Pharma to deliver Digimarc's Media Enhanced Packing solutions

Digimarc Corporation has licensed its mobile visual search software to New Jersey-based Catalent Pharma Solutions, a leading provider of innovative packaging solutions to the pharmaceutical, biotechnology, and consumer healthcare industries.

28 Sep 2010

Health Council of Canada applauds Nova Scotia for initiative towards ensuring low drug prices

The Health Council of Canada applauds the Nova Scotia Department of Health for their steps towards ensuring low drug prices in their province. The plan includes meeting with groups, such as community pharmacies, doctors, medical staff at health authorities, senior groups and drug manufacturers for input on how to lower prices for prescription drugs and contain drug costs.

24 Sep 2010

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Teva Pharmaceutical Industries Ltd. announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

22 Sep 2010

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from a 36-week active extension study evaluating two doses of laquinimod, an investigational, once-daily oral immunomodulator, for the treatment of relapsing remitting multiple sclerosis.

21 Sep 2010

Opiate usage increases in workplace and ER

More American workers and job applicants are testing positive for prescription opiates, according to U.S. general workforce data in the 2009 annual Drug Testing Index™ (DTI) released today by Quest Diagnostics Incorporated, the nation's leading provider of diagnostic testing, information and services. Results from more than 5.5 million urine drug tests reveal an 18 percent jump in opiate positives in the general U.S. workforce in a single year (2008 to 2009), and a more than 40 percent climb from 2005 to 2009.

17 Sep 2010

Elite Pharmaceuticals signs agreements with Precision Dose for four generic products

Elite Pharmaceuticals, Inc. announced today the signing of a license agreement and a manufacturing and supply agreement with Precision Dose, Inc. which has a wholly owned subsidiary, TAGI Pharma, Inc. which will distribute the products covered by the agreement. Pursuant to the License Agreement, TAGI Pharma will market and sell four Elite generic products in the United States, Puerto Rico and Canada.

17 Sep 2010

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

The Academy of Managed Care Pharmacy (AMCP) supports the inclusion of legislative language similar to S. 369 — the Preserve Access to Affordable Generics Act — in appropriations legislation now under consideration by the Senate. S. 369 would prohibit financial agreements between brand-name and generic pharmaceutical manufacturers to delay the marketing of lower-cost generic drugs.

14 Sep 2010

Walgreens August sales increase 8.6% to $5.66 billion

Walgreens had August sales of $5.66 billion, an increase of 8.6 percent from $5.22 billion for the same month in 2009. Duane Reade stores, acquired in April 2010, contributed 2.8 percentage points to the total sales increase for the month.

3 Sep 2010

Study determines dose-specific patterns associated with generic statin switching

Research conducted in the Netherlands has highlighted the need for care when switching patients under treatment for high cholesterol from branded to generic drug families. The study shows that much of the switching can result in patients inadvertently receiving non-equivalent doses, potentially leading to an increased risk of downstream heart disease and stroke.

31 Aug 2010

Ralphs Grocery Company to offer seasonal flu vaccine at $25

Ralphs Grocery Company is making it easy and affordable for customers to stay healthy by getting seasonal flu immunizations early.

31 Aug 2010

Ipsen 2010 first half revenue increases to €31.7 million

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on August 30, 2010 to review the Group's results for the first half 2010, published today

31 Aug 2010

Humana and Availity deploy CarePrescribe to Kentucky Physicians at no charge

Humana Inc. and Availity, LLC today announced the deployment of CarePrescribe, an electronic prescribing service, at no charge to eligible physician practices in Kentucky. Following the successful introduction of Availity CarePrescribe in Florida and Texas - where approximately 2,000 physicians are using the system - Kentucky physicians now have access to the free service as a valuable tool in improving efficiency, safety and quality, while reducing patient costs.

24 Aug 2010

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

Jiangbo Pharmaceuticals, Inc., today announced that the Company received approval from the Shandong Food and Drug Administration to start the sales of Felodipine sustained release tablets.

16 Aug 2010

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration to expand the number of licenses for the Company's DDDPlus™ simulation software.

13 Aug 2010

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.

10 Aug 2010

Teva completes ratiopharm acquisition

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of ratiopharm, Germany's second largest generics producer. Following the acquisition, Teva will be the number one generic company in Europe, holding the leading market position in ten countries, as well as ranking in the top three in seven additional countries. In addition, the transaction will significantly increase Teva's sales in Canada.

10 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

Generic Drug News and Research

Further Reading

FDA takes action against unapproved single-ingredient oral colchicine

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Catalent Pharma to deliver Digimarc's Media Enhanced Packing solutions

Health Council of Canada applauds Nova Scotia for initiative towards ensuring low drug prices

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Opiate usage increases in workplace and ER

Elite Pharmaceuticals signs agreements with Precision Dose for four generic products

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

Walgreens August sales increase 8.6% to $5.66 billion

Study determines dose-specific patterns associated with generic statin switching

Ralphs Grocery Company to offer seasonal flu vaccine at $25

Ipsen 2010 first half revenue increases to €31.7 million

Humana and Availity deploy CarePrescribe to Kentucky Physicians at no charge

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Teva completes ratiopharm acquisition

TEMPO study recommends early administration of Azilect in PD patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News